Yearly Archives: "2015"

EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Pfizer & Synthon enter Into U.S. commercialization agreement for treatment of multiple sclerosis
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today [...]
FDA: Gadolinium-based MRI contrast agents pose possible brain risk
A statement from our CMSC leadership: While the implications for MS patient care may need to be re-evaluated and changed in the future [...]
Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition announces new board President
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]
Novartis statement on reported case of PML
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Mallinckrodt research fellowship award program announcement
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM